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Abstract 
Background: Qing‑dai powder (QDP), comprising Indigo naturalis (Qing‑dai) and dried alum (Ku‑fan), was used in 
Chinese medicine to treat the conditions associated with mucosal hemorrhage, such as ulcerative colitis (UC). This 
study aims to investigate the effects and potential mechanism of QDP on dextran sulfate sodium (DSS)‑induced acute 
colitis in mice and to examine the regulatory effects of QDP on macrophages.
Methods: Seven‑ to eight‑week‑old male C57BL/6 mice were challenged with 2.0 % DSS in drinking water for 
5 days and then the colitic mice were arbitrarily allocated into five groups (n = 10 for each group). QDP (0.77, 1.54 
and 3.08 g/kg) and sulfasalazine (SASP) (0.20 g/kg) were orally administered for 7 days. The disease activity index was 
determined by scores of body weight loss, diarrhea and rectal bleeding; histological signs of damage was analyzed by 
H&E staining; myeloperoxidase activity was measured by colorimetric method, levels of proinflammatory cytokines 
were determined by ELISA; changes in macrophages in the colon were analyzed by immunohistochemistry (IHC) and 
flow cytometry. Lipopolysaccharide (LPS)‑induced RAW264.7 cells were treated with or without QDP, then the produc‑
tion of TNF‑α and IL‑6 were measured by ELISA; and protein molecules such as COX‑2, iNOS, IкB‑α were determined 
by Western blot.
Results: Oral administration of QDP at dosages of 1.54 and 3.08 g/kg significantly reduced disease activity index on 
day 12 (P < 0.001 for 1.54 g/kg and P < 0.0008 for 3.08 g/kg), colon shortening (P = 0.012 for 1.54 g/kg, P = 0.001 for 
3.08 g/kg), histological damage (P < 0.001 for 1.54 g/kg, P < 0.001 for 3.08 g/kg) and colonic myeloperoxidase activ‑
ity (P = 0.002 for 1.54 g/kg, P < 0.001 for 3.08 g/kg) of DSS‑treated mice. Moreover, QDP treatment (1.54 and 3.08 g/
kg) significantly decreased DSS‑induced infiltration of macrophages, and production of TNF‑α (P = 0.005 for 1.54 g/
kg, P = 0.002 for 3.08 g/kg), IL‑1β (P = 0.008 for 1.54 g/kg, P = 0.002 for 3.08 g/kg) and IL‑6 (P = 0.011 for 1.54 g/kg, 
P = 0.004 for 3.08 g/kg) in colonic tissues, and also reduced serum MCP‑1 levels (P = 0.001 for 1.54 g/kg, P < 0.001 for 
3.08 g/kg). In RAW264.7 cells, QDP significantly suppressed LPS‑induced production of TNF‑α and IL‑6 (Both P < 0.001 
for 1.0 μg/mL QDP treatment) and expression levels of COX‑2 (P = 0.002 and P = 0.001 for 1 and 3 μg/mL QDP treat‑
ment, respectively) and iNOS (P < 0.001 for 3 μg/mL QDP treatment) by inhibiting IкB‑α degradation (P = 0.007 and 
P = 0.004 for 1 and 3 μg/mL QDP treatment, respectively) and NF‑кB p65 nuclear translocation.
Conclusion: QDP suppressed the inflammatory responses of colonic macrophages in DSS‑induced UC in mice and 
LPS‑induced RAW264.7 cells.
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Background
Ulcerative colitis (UC), a subtype of inflammatory bowel 
disease (IBD), is a chronic uncontrolled inflammatory 
condition of the intestinal mucosa [1], progressively 
increasing in the incidence rates worldwide [2, 3]. The 
refractory relapses are due to lack of effective treatment 
[4]. Current medical therapies for UC mainly focus on 
inducing remission and preventing relapse [5]. Amino-
salicylates [sulfasalazine (SASP) and 5-aminosalicylic 
acid (5-ASA)], corticosteroid (prednisolone) and thio-
purines (azathioprine and 6-mercaptopurine) are com-
monly recommended as the standard treatments for UC 
patients [6]. In addition, infliximab and tacrolimus have 
been used for treating UC patients since 1998 and 2006, 
respectively [7].
IBD is subject to environmental factors, genetic deter-
minants, microbial exposures and immunoregulatory 
defects [8]. IBD develops when an excessive immuno-
logical reaction in the mucosal immune system respond 
towards luminal antigens such as dietary factors, com-
mensal bacteria or both in genetically susceptible hosts 
[9]. Innate immunity is involved during the onset and in 
the regulation of the severity of IBD. In the development 
of IBD, the innate immune response increased levels of 
proinflammatory cytokines and chemokines, including 
TNF-α, IL-1β and IL-6, exaggerating adaptive immune 
responses, and resulting in tissue injury and clinical 
symptoms [10, 11].
A significant increase in the number of macrophages 
was observed in the inflamed tissue and peripheral blood 
vessels of IBD patients [12, 13]. During the development 
of acute colitis in animal models, accumulated mac-
rophages were also observed in the inflamed gut [14, 15]. 
Interleukins or growth factors at sites of inflammation 
activated clusters of macrophages, which subsequently 
secrete a variety of proinflammatory cytokines, result-
ing in persistent intestinal inflammation [16]. Depletion 
of macrophages in dextran sulfate sodium (DSS)-induced 
colitis in mice halted the development of colitis [17]. 
Thus, suppressing intestinal macrophages could be a 
promising therapeutic approach to treating IBD.
Qing-dai powder (QDP) is a herbal medicinal formula 
comprising Indigo naturalis (Qing-dai) and dried alum 
(Ku-fan), for treating hematemesis and hemorrhinia 
[18]. QDP and its modified formulas are clinically used 
to treat colitis in China [19–21]. From 2009 to 2013, we 
at Hong Kong Baptist University Mr. and Mrs. Chan Hon 
Yin Chinese Medicine Specialty Clinic and Good Clinical 
Practice Centre prescribed QDP to patients with intrac-
table UC in clinical practice who had failed to respond to 
treatment with 5-ASA, prednisolone or infliximab. We 
gave QDP at a dosage of 7.5  g/day (loaded in capsules, 
orally, twice a day) for 1–2 weeks. There was a study on 
indirubin 3′-monoxime, a derivative compound of the 
active component indirubin isolated from I. naturalis, 
observed the compound significantly inhibited the pro-
duction of pro-inflammatory mediators induced by LPS 
in RAW264.7 cells through down-regulating NF-кB and 
JNK signaling pathways [22]. The regulation of mac-
rophage function could be involved in the effect of QDP. 
The effects and potential mechanism of QDP has not yet 
been assessed in animal studies.
This study aims to investigate the effects and poten-
tial mechanism of QDP on DSS-induced acute colitis in 




DSS (molecular weight: 36,000–50,000 Daltons) was 
purchased from MP Biologicals (Santa Ana, USA). 
Dimethylsulphoxide (DMSO), lipopolysaccharide (LPS) 
(Escherichia coli Serotype 055:B5), sulfasalazine (SASP) 
(purity ≥ 98 %), hexadecyltrimethylammonium bromide, 
hematoxylin, eosin, O-dianisidine dihydrochloride, pro-
tease inhibitor cocktails and hydrogen peroxide were 
purchased from Sigma-Aldrich (St, Louis, MO, USA). 
Fetal bovine serum, l-glutamine, penicillin, streptomy-
cin and RPMI 1640 cell culture medium were purchased 
from Invitrogen (Carlsbad, CA, USA). Antibodies against 
COX-2, iNOS, IκB α and p65 and β-actin were supplied 
from Cell Signaling Technology, Inc. (Beverly, MA, USA). 
TNF-α, IL-1β, and IL-6 ELISA kits were purchased from 
eBioscience (San Diego, CA, USA). Cy5.5 PerCP anti-
mouse CD11b, FITC anti-mouse F4/80 were purchased 
from BD Pharmingen (San Diego, CA, USA). FITC-
conjugated donkey anti-rabbit IgG antibody was pur-
chased from Santa Cruz Biotechnology (Santa Cruz, CA, 
USA). WesternBright™ ECL was supplied from Advansta 
(Menio Park, CA, USA).
Preparation of QDP
The ratio of I. naturalis and dried alum in QDP is 2:1. 
Two Chinese medicinal raw herbs were obtained from 
the dispensary of Traditional Chinese Medicine, Clini-
cal Division, School of Chinese Medicine, Hong Kong 
Baptist University, Hong Kong. These two Chinese 
medicinal materials were authenticated by Dr. Hu-Biao 
Chen (School of Chinese Medicine, Hong Kong Bap-
tist University, Hong Kong) according to the Chinese 
Pharmacopoeia (version 2010) and other references 
[23–25]. Voucher specimens (nos. TCM-0110-Q01, 
TCM-0110-Q02) are stored in our Research Laboratory, 
School of Chinese Medicine, Hong Kong Baptist Uni-
versity, Hong Kong. Two herbs were mixed, powdered 
to homogeneous size in a mill and sieved through a 
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120-mesh filter. Each sample was exactly weighed, ultra-
sonically extracted with DMSO in a KQ-2200DB ultra-
sonic cleaner bath (Kunshan Ultrasound Instrument Co., 
Ltd., Jiangsu, China), and filtered through a syringe filter 
for subsequent UPLC-QTOF-MS analysis and cell culture 
treatment. For animal study, QDP was freshly suspended 
in 0.5  % sodium carboxymethylcellulose (CMC-Na) in 
distilled water prior to oral feeding to mice.
Ultra‑performance liquid chromatography quadrupole 
time‑of‑flight mass spectrometry (UPLC‑QTOF‑MS) analysis
The components in QDP were identified by UPLC-
QTOF-MS. Chromatographic separation was per-
formed by an Agilent 1290 Infinity UPLC system 
(Santa Clara, CA, USA), equipped with a binary sol-
vent delivery system, a standard auto-sampler and pho-
todiode array detectors (DAD). A 100  mm ×  2.1  mm 
ACQUITY BEH C18 1.7-µm column (Waters Corp., 
Milford, MA, USA) was used to separate the compo-
nents of QDP. The mobile phase consisted of (A) 0.1 % 
formic acid in water and (B) 0.1 % formic acid in ace-
tonitrile. A linear gradient was optimized as follows 
(flow rate, 0.40  mL/min): 0–2.5  min, 2–5  % B; 2.5–
10 min, 5–35 % B; 10–20 min, 35–75 % B; 20–23 min, 
75–100  % B; 23–26  min, 100  % B; 26–26.1  min, 
100–2 % B; 26.1–30 min, 2 % B. The injection volume 
was 2 μL and the column temperature was maintained 
at 40  °C in each run. Mass spectrometry was per-
formed by an Agilent 6540 ultra-high definition (UHD) 
QTOF mass spectrometer, equipped with a Jet Stream 
electrospray ionization (ESI) source. Parameters for 
the Jet Stream technology were set with the super-
heated nitrogen sheath gas temperature at 350 °C and 
with a flow rate at 10 L/min. ESI conditions were set 
as follows: negative ion mode, capillary 4500 V, nebu-
lizer 1.85685 × 106 kPa, drying gas 8 L/min, gas tem-
perature 300 °C, nozzle voltage 300 V, skimmer voltage 
65 V; octapole RF peak 600 V, fragmentor 175 V. Mass 
spectra were recorded across the range m/z 100–1700 
with accurate mass measurement of all mass peaks. A 
sprayer with a reference solution was used for continu-
ous calibration in negative ion mode with reference 
masses at m/z 112.9856 and 966.0007. The full-scan 
and MS/MS data were processed with Agilent Mass 
Hunter Workstation software (version B.02.00) (Santa 
Clara, CA, USA).
Cell culture
RAW264.7 murine macrophage cells were obtained from 
the American Type Culture Collection (ATCC No. TIB-
71). The cell line was cultured in RPMI 1640 cell cul-
ture medium supplemented with 10 % (v/v) fetal bovine 
serum, 2  mM  l-glutamine, 100 U/mL penicillin G and 
100 μg/mL streptomycin. The cells were incubated in a 
humidified 5 % CO2 incubator at 37 °C.
Animals
Seven to eight-week-old male C57BL/6 mice weighing 
20–24  g were purchased from the Laboratory Animal 
Services Center, The Chinese University of Hong Kong. 
The animals were fed a standard rodent diet with free 
access to water, and were kept in rooms maintained at 
21–23  °C with a 12  h light/dark cycle following inter-
national recommendations. All experimental protocols 
were approved by the Animal Ethics Committees of 
Hong Kong Baptist University, in accordance with “Insti-
tutional Guidelines and Animal Ordinance” (Department 
of Health, Hong Kong Special Administrative Region).
Induction of colitis and treatment
Acute colitis was induced by oral administration of 2.0 % 
(w/v) DSS dissolved in drinking water, for 5 days accord-
ing to Wirtz et al. [26]. Mice of each experimental group 
were monitored every day to confirm that they consumed 
equal volumes of DSS-containing water.
Two sets of experiments were performed. For the first 
one, 50 colitic mice were arbitrarily allocated into 5 
groups: DSS model group, sulfasalazine (SASP, positive 
reference agent)-treated group, and three QDP-treated 
groups (n = 10). A vehicle control group with nine nor-
mal mice received drinking water without DSS through-
out the entire experimental period. Consistent with 
clinical treatment, QDP was administrated orally to coli-
tic mice at doses of 0.77, 1.54 or 3.08 g/kg/day, compara-
ble with the clinical dosages used in human UC patients. 
SASP was used as a positive reference agent and it was 
given at 0.20  g/kg/day according to Kim et  al. [27]. The 
gavage volume was 0.4 mL.
For the second set of experiments to immunophe-
notype colonic macrophages in colonic lamina pro-
pria, twelve colitic mice were arbitrarily allocated into 2 
groups: DSS model group (n  =  6) and 1.54  g/kg QDP-
treated group (n = 6). A vehicle control group of 5 nor-
mal mice received drinking water only during the entire 
experimental period. Both SASP and QDP were dissolved 
in 0.5 % sodium carboxymethylcellulose (CMC-Na) solu-
tion and administrated orally to the mice for 7 days after 
the onset of colitis. The vehicle control group and DSS 
model group were fed with 0.4  mL of 0.5  % CMC-Na 
solution instead of SASP or QDP.
Evaluation of disease activity index (DAI)
Body weight, stool consistency and rectal bleeding were 
recorded daily. The DAI was determined by combining 
the scores of (1) body weight, (2) stool consistency and 
(3) rectal bleeding [28].
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Histological analysis
Colon tissues were harvested and fixed in 4.0 % paraform-
aldehyde. Tissue sections were prepared by conventional 
tissue processing methods, stained with hematoxylin and 
eosin (H&E), and examined under the light microscope. 
Colonic damage was assessed as described previously 
[28].
Determination of colonic myeloperoxidase (MPO) activity
MPO activity was measured as described in our previ-
ous study [28]. One unit of MPO activity was defined as 
the amount of enzyme present that produced a change in 
optical density of 1.0 U/min at 25 °C in the final reaction 
volume. The results were normalized to equal protein 
levels and quantified as units/mg protein.
Immunohistochemical analysis
Colonic tissues were fixed in 4.0  % buffered paraform-
aldehyde, embedded in paraffin and sectioned into 
5-μm-thick slices. Sectioned samples were deparaffinized 
in xylene, rehydrated in a series of graded alcohol, and 
subjected to antigen retrieval. Antigens were retrieved by 
incubation with protease K solution (1: 100) for 20 min.
Endogenous peroxidase was quenched with 3.0  % 
hydrogen peroxide in methanol for 30 min. Sections were 
further blocked with 3.0 % bovine serum albumin (BSA) 
in PBS, exposed to 0.5 % Triton X-100 for 1 h for reduc-
ing nonspecific antibody binding and incubated with 
mouse F4/80 antibody (AbD serotec, Raleigh, North Car-
olina, USA) at 4 °C overnight. The sections were washed 
with PBS three times, incubated with biotinylated anti-
rabbit immunoglobulins, followed by peroxidase-labeled 
streptavidin, and 3, 3′-diaminobenzidine chromogen sub-
strate added to make antibody binding visible according 
to the protocol of the LSAB kit (LSAB-DAKO, Copenha-
gen, Denmark). Sections were then washed with PBS and 
counterstained with hematoxylin. After dehydration with 
a series of increasingly concentrated ethanol, sections 
were mounted with neutral gum. Five random fields at 
400× magnification were counted in each sectioned sam-
ple by a researcher blinded to the treatment. The number 
of macrophages per μm2 of mucosa was quantified by the 
Image J software (National Institutes of Health, Bethesda, 
Maryland, USA).
Immunophenotyping of colonic macrophages
Colonic lamina propria cells were isolated as previously 
described with slight modifications [29, 30]. The colons 
were removed from mice immediately after euthana-
sia. Subsequently, the colonic tissues were immersed in 
DMEM containing 100 U/mL of penicillin and 100 μg/
mL of streptomycin, dissected longitudinally and cut into 
0.5–1-cm pieces. Then, intestinal epithelial cells were 
dissociated by incubation with Ca2+ and Mg2+-free HBSS 
containing 5  mM EDTA and 1  mM DTT for 20  min at 
37  °C, twice. After thorough washing with PBS, colonic 
tissues were then incubated with digestion buffer (RPMI 
1640 containing 3  mg/mL dispase II, 0.5  mg/mL colla-
genase D, and 0.5 mg/mL DNase I) for 30 min at 37 °C, 
twice. Finally, the cells were labeled with anti-CD11b and 
anti-F4/80 antibodies, and analyzed by flow cytometry. 
Appropriate isotype-matched IgGs were used as negative 
controls.
Enzyme‑linked immunosorbent assay (ELISA) analysis
The cytokines TNF-α, IL-1β and IL-6 in the culture 
supernatants of RAW264.7 cells and colonic tissues and 
the chemokine monocyte chemoattractant protein-1 
(MCP-1) in serum samples were measured with TNF-α, 
IL-1β, IL-6 and MCP ELISA kits, respectively (eBiosci-
ence, San Diego, CA, USA) according to the manufac-
turer’s protocols.
Western blot analysis
After treatment with a range of concentrations of QDP 
(0.3–3  μg/mL) in the presence or absence of 1  μg/mL 
LPS, RAW264.7 cells were analyzed by immunoblotting 
as described previously [31]. Primary antibodies that 
recognize iNOS, COX-2 and IκB-α were used, and spe-
cific proteins were detected by WesternBright™ ECL. 
Equal loading was assessed by a β-actin antibody, and the 
amount of total protein present was normalized to the 
level of β-actin.
Cellular localization of nuclear factor kappa B (NF‑κB) p65
RAW264.7 cells were cultured directly on glass cover 
slips in a 35-mm dish for 24 h and pretreated with QDP 
for 1 h in the presence or absence of 1 μg/mL LPS. Cells 
were fixed with 4 % paraformaldehyde, treated with 0.2 % 
Triton X-100, and blocked with 3 % BSA. Subsequently, 
cells were incubated with a rabbit anti-NF-κB p65 poly-
clonal antibody (1:100) at 4 °C overnight. After extensive 
washing with PBS, cells were further incubated with a 
secondary FITC-conjugated donkey anti-rabbit IgG anti-
body (1:100) for 1  h at room temperature. Nuclei were 
counterstained with DAPI solution (1 μg/mL), and cells 
were analyzed by a fluorescence microscope (Carl Zeiss, 
Oberkochen, Germany).
Statistical analysis
The data were presented as mean ± standard deviation (SD). 
Statistical differences among groups were evaluated by one-
way analysis of variance (ANOVA) and Duncan’s multiple 
range test by SPSS 16.0 statistical software (SPSS Inc., Chi-
cago, IL, USA). P values <0.05 were considered statistically 
significant. Dose-dependence was visually determined.
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Results
Identification of chemical components of QDP
Under the optimized conditions [32], the major compo-
nents in QDP were well separated and detected within 
30 min (Table 1). Taking retention time (tR), m/z, ultra-
violet (UV) absorption characteristics (lambda max), and 
relevant references into consideration, 27 peaks repre-
senting individual chemical components were identified. 
The representative chromatograms, monitored by DAD 
and MS, are shown in Fig. 1.
QDP attenuates the severity of DSS‑induced colitis
Oral administration of 2.0  % DSS in drinking water 
resulted in high mortality; up to 30.0 % of the total mice 
in the DSS model group died. QDP treatment could 
reduce the mortality rate of DSS-treated mice, to 20.0, 
10.0 and 10.0 % for low-, medium- and high-dose QDP-
treated groups, respectively (Fig.  2a). Starting from day 
5, DSS resulted in rapid loss of body weight and seri-
ous clinical disease symptoms (diarrhea and occult fecal 
blood) in C57BL/6  J mice, and lasted 3–4  days. After 
that, mice began to recover. QDP treatment improved 
body weight recovery and DAI of DSS-treated mice, 
particularly in the medium- and high-dose QDP treat-
ment groups when compared with the DSS model group 
(both P < 0.001) (Fig. 2b, c). In addition, the DSS-induced 
model of colitis is associated with a marked decrease in 
colon length [28]. Treatment with QDP significantly pre-
vented colon shortening in a dose-dependent manner 
(P = 0.020, P = 0.012, P = 0.001, respectively) (Fig. 2d).
QDP decreases colonic tissue damage and reduces colonic 
MPO activity
As shown in Fig. 3, 2.0 % DSS in drinking water caused 
extensive colonic tissue damage, including inflam-
matory cell infiltration, lesion formation and crypt 
destruction. Mice receiving QDP treatment showed 
less colonic damage. Scores of the histological changes 
are displayed in Fig.  3g. The score was significantly 
higher for the DSS model group than that for the 
vehicle-treated control group, i.e., reducing inflam-
mation and mucosal and crypt damage in the colon, in 
Table 1 Main components of QDP
Peak tR (min) Assigned identity Molecular formula
1 0.999 Butanedioic acid C4H6O4
2 5.775 Isatin C8H5NO2
3 5.908 2,3‑Dihydro‑4‑hydroxy‑2‑oxo‑1H‑indole‑3‑acetic acid C10H8N2O2
4 6.511 Deoxyvascinone C11H10N2O
5 7.729 10H‑indolo [3, 2‑b] quinoline C15H10N2
6 8.436 2,3‑Dihydro‑3,4‑dihydroxy‑2‑oxo‑1H‑indole‑3‑acetonitrile, 3‑Cyanomethyl‑3,4‑dihydroxyoxindole C10H8N2O3
7 8.856 3‑(2‑Hydroxyphenyl)‑4(3H)‑quinazolinone C14H10N2O2
8 8.995 10H‑indolo[3,2‑b]quinoline‑11‑carboxylic acid amide C16H11N3O
9 9.589 Tryptanthren C15H8N2O2
10 11.515 Syringin C17H24O9
11 11.909 3‑(2‑Carboxyphenyl)‑4(3H)‑quinazolinone C15H10N2O3
12 13.240 Indigo C16H10N2O2
13 13.972 Indican C14H17NO6
14 14.185 Indirubin C16H10N2O2
15 14.658 2‑[Cyano(3‑indolyl)methylene]‑3‑indolone C18H11N3O
16 16.612 8,11,12‑Trihydroxy‑9‑octadecenoic acid C19H36O5
17 17.883 Anthranilic acid C7H7NO2
18 18.492 Salicylic acid C7H6O3
19 19.161 Octadecanoic acid C18H36O3
20 19.343 Bisindigotin C32H18N4O2
21 20.550 Qingdainone C23H13N3O2
22 20.854 Betulin C30H50O2
23 21.463 Sugiol C20H28O2
24 22.801 Rotenol C23H24O6
25 23.417 Sitosterol C32H53N7O2
26 24.686 Daucosterol C35H60O6
27 26.836 Clerosterol C29H48O
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particular in those mice treated with medium and high 
doses of QDP (both P  <  0.001). Consistent with the 
histological scores, colonic MPO activity was greatly 
increased in the DSS model group (P < 0.001), whereas 
the MPO activities in the QDP-treated groups were 
significantly suppressed in a dose-dependent manner 
(Fig. 3h).
QDP decreases infiltration of macrophages in the colon 
of DSS‑treated mice
The infiltration of macrophages in the colon was ana-
lyzed with the macrophage marker F4/80. The number 
of macrophages in the colons of model group mice was 
significantly higher than in the normal group (P < 0.001) 
(Fig.  4A). Compared with the model group, there were 
considerably fewer macrophages in the colons of QDP-
treated mice (P  =  0.003, P  <  0.001 and P  <  0.001 for 
0.77, 1.54 and 3.08  g/kg QDP, respectively). Similar to 
the results of the immunohistochemical study, the num-
ber of macrophages was increased after DSS treatment 
(P < 0.001), and QDP at 1.54 g/kg significantly decreased 
the recruitment of macrophages to the colon lamina pro-
pria of the DSS-treated mice (P = 0.004) in flow cytom-
etry (Fig. 4B).
QDP suppresses colonic proinflammatory cytokine 
production and serum MCP‑1 levels in DSS‑treated mice
Levels of macrophage-associated proinflammatory 
cytokines such as TNF-α, IL-1β and IL-6 were meas-
ured in the colonic tissues to ascertain the suppressive 
effects of QDP on colonic macrophages. The levels of 
colonic TNF-α, IL-1β and IL-6 were significantly higher 
in the DSS model group (all P < 0.001), and QDP treat-
ment significantly lowered the production of TNF-α, 
IL-1β and IL-6 in colonic tissue of DSS-treated mice 
(Fig.  5a–c). Oral administration of 2.0  % DSS in drink-
ing water resulted in a sharp increase of MCP-1 in the 
serum of DSS-treated mice. Treatment with QDP greatly 
reduced serum MCP-1 levels in a dose-dependent man-
ner (Fig. 5d).
QDP inhibits LPS‑induced TNF‑α and IL‑6 production 
and expression of iNOS and COX‑2 in RAW264.7 cells
Macrophages are a major source of proinflammatory 
cytokines, including TNF-α, IL-1β and IL-6. We therefore 
evaluated the anti-inflammatory effect of QDP on LPS-
stimulated RAW264.7 cells (murine macrophage cell line). 
Treatment with LPS resulted in significantly increased 
production of proinflammatory cytokines (by 2.0-fold for 
Fig. 1 Elementary particle flow graph (BPI) chromatogram monitored in positive ion mode for QDP
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TNF-α; by 14.3-fold for IL-6) (both P < 0.001) in culture 
supernatants of RAW264.7 cells, while QDP at a concen-
tration of 1  μg/mL significantly inhibited LPS-induced 
production of TNF-α and IL-6 (both P < 0.001) (Fig. 6a).
The activities of iNOS and COX-2 are the immediate 
modulators of NO and PGE2, respectively, produced by 
macrophages for the initiation and progression of IBD 
[33]. We investigated the effects of QDP on the expres-
sion of iNOS and COX-2 by Western blot analysis. Pro-
tein levels of iNOS and COX-2 were upregulated in 
response to LPS (Both P  <  0.001), and treatment with 
QDP resulted in dose-dependent inhibition of iNOS and 
COX-2 protein expression (Fig. 6b).
QDP blocks LPS‑induced IκB‑α degradation and p65 
nuclear translocation
We examined the effect of QDP on LPS-induced deg-
radation of IκB-α by Western blotting. The degradation 
of IκB-α after LPS treatment was inhibited by QDP in a 
dose-dependent manner (Fig. 7a).
Furthermore, we investigated the effect of QDP on 
LPS-induced p65 nuclear translocation by immuno-
fluorescence. p65 was normally sequestered in the 
cytoplasm, while LPS induced p65 accumulation in 
the nucleus. However, pre-treatment with QDP abol-
ished LPS-induced p65 translocation to the nucleus 
(Fig. 7b).
Fig. 2 Effects of QDP on mortality a body weight change; b disease activity index; c and colon length; and d of mice with DSS‑induced colitis. 
Colitis was induced in all groups except control group. QDP and SASP were administered to mice from day 6 to 12. The change in body weight was 
taken as the difference between the body weight before induction of colitis and that immediately before sacrifice on day 13. Disease activity index 
was determined by combining scores of (1) body weight loss; (2) stool consistency; and (3) stool blood. On day 13, mice were sacrificed, and colon 
length was measured. Survival data of challenged mice were collected from 9 to 10 mice respectively, and other data were expressed as mean ± SD 
(n = 7–9). ###P < 0.001, compared with control group; *P < 0.05, **P < 0.01 and ***P < 0.001, compared with DSS model group
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Discussion
Oral administration of QDP suppressed colonic mac-
rophage recruitment and activation to attenuate the 
severity of DSS-induced colitis in mice, as evidenced by 
reduced mortality, clinical manifestations, colon short-
ening, histological damage and colonic myeloperoxidase 
activity.
The DSS-induced colitis mouse model is simple 
and reproducible, and is commonly used to study the 
pathogenesis of UC, and screen potential therapeu-
tic interventions [34]. Using this model, we found that 
QDP could significantly attenuate clinical symptoms 
of DSS-treated mice including body weight loss, stool 
consistency and bleeding. Furthermore, QDP signifi-
cantly prevented colon shortening and colon tissue dam-
age induced by DSS. Oral administration of QDP could 
attenuate the colonic MPO activity of DSS-treated mice 
in a dose-dependent manner.
Fig. 3 Effects of QDP on histopathological changes and MPO activity in colon of mice with DSS‑induced colitis. a control; b DSS model; c SASP; d 
0.77 g/kg QDP; e 1.54 g/kg QDP; f 3.08 g/kg QDP (magnification, ×100); g histological score; and h MPO activity. Colitis was induced in all groups 
except control group. QDP and SASP were administered to mice from day 6 to 12. On day 13, mice were sacrificed, and colonic tissue damage was 
evaluated by histopathological analysis (H&E staining). MPO activity was determined in colonic homogenates. Data were expressed as mean ± SD 
(n = 7–9)
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In the inflamed gut, macrophages secrete excessive pro-
inflammatory cytokines to initiate the innate immune 
response and the consequential adaptive immune 
response [14, 16]. In the present study, treatment with 
2.0  % DSS resulted in an increase of macrophages in 
colon tissues, and oral administration of QDP could 
significantly suppress macrophage accumulation. The 
accumulated macrophages in the inflamed colon were 
Fig. 4 Effects of QDP on macrophage infiltration in colons of DSS‑treated mice. A Immunohistochemical (IHC) analysis of colonic macrophages 
by F4/80 marker [a–f representative images (a control; b DSS model; c SASP; d 0.77 g/kg QDP; e 1.54 g/kg QDP; and f 3.08 g/kg QDP), g number of 
macrophages]; B flow cytometric analysis of macrophages in the colon lamina propria (LP) (a control; b DSS model; c 1.54 g/kg QDP; and d percent‑
age of macrophages in total LP cells). Colitis was induced in all groups except control group. QDP and SASP were administered to mice from day 6 
to 12. On day 13, mice were sacrificed. The colon section was evaluated by IHC analysis with F4/80 marker (n = 7–9). For flow cytometric analysis, 
the population of macrophage in lamina propria mononuclear cells from whole colonic tissue was determined by CD11b and F4/80 markers (n = 5 
for normal control group, and n = 6 for DSS‑treated groups). Data were expressed as mean ± SD
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recruited and differentiated from Ly6Chi monocytes in 
the bloodstream, and are different from resident intesti-
nal macrophages and represent a proinflammatory phe-
notype [15]. Their recruitment was mediated by MCP-1, 
which binds to the chemokine receptor CCR2 on cir-
culating monocytes to attract monocytes to inflamed 
tissues [15, 35]. We observed that 2.0  % DSS treatment 
increased serum MCP-1 levels and QDP treatment could 
significantly reverse this increase. Accumulated colonic 
macrophages were activated in the context of gut inflam-
mation, resulting in excessive secretion of proinflamma-
tory cytokines, such as TNF-α, IL-1β and IL-6, which 
exacerbate IBD [35]. QDP could significantly suppress 
the production of TNF-α, IL-1β and IL-6 in the colons of 
DSS-treated mice. In RAW264.7 cells, QDP could signifi-
cantly decrease LPS-induced TNF-α and IL-6 production 
and expression of iNOS and COX-2 by inhibiting IκB-α 
degradation and NF-κB p65 translocation.
SASP is used clinically for mild-to-moderate UC 
patients via anti-inflammatory, immunomodulatory prop-
erties or both [36]. In the present study, QDP at a dose 
of 1.54  g/kg exhibited an effect comparable with SASP 
(200  mg/kg) against DSS-induced colitis in mice. This 
beneficial effect was associated with its anti-inflamma-
tory activity through suppression of colonic macrophage 
recruitment and activation. Therefore, QDP could be ben-
eficial to mice, in addition to human, as a study model for 
developing effective pharmaceuticals to treat UC.
Fig. 5 Effects of QDP on colonic production of pro‑inflammatory cytokines and serum MCP‑1 level in DSS‑treated mice (a colonic TNF‑α; b colonic 
IL‑6; c colonic IL‑1β; and d serum MCP‑1). QDP and SASP were administered to mice from day 6 to 12. On day 13, mice were sacrificed, amounts of 
various cytokines in colonic homogenates and MCP‑1 levels in serum were determined by ELISA. Data were expressed as mean ± SD (n = 7–9)
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Fig. 6 Effects of QDP on LPS‑induced production of TNF‑α and IL‑6 and expression of iNOS and COX‑2 in RAW264.7 cells. Cells were treated with 
QDP for 1 h, followed by continuous incubation with LPS (1 μg/mL) for 24 h. a Concentrations of TNF‑α and IL‑6 in culture medium were monitored 
by ELISA. b Cells were lysed and expression of iNOS and COX‑2 were determined by Western blotting. Data represent the mean ± SD (n = 3). The 
images shown are representatives of three independent experiments
Fig. 7 Effects of QDP on LPS‑induced IκB α degradation and p65 nuclear translocation. a Cells were pretreated with the indicated concentrations 
of QDP for 1 h and incubated with LPS (1 μg/mL) for another 30 min. Cells were lysed and IκB α expression was determined by Western blot. b Cells 
were pretreated with 1 μg/mL QDP for 1 h prior to stimulation with LPS (1 μg/mL) for 1 h. The nuclear localization of p65 was determined using 
fluorescence microscopy after staining with DAPI, anti‑p65, and FITC‑labeled anti‑rabbit IgG antibody (p65 sequestered in the cytoplasm were indi‑
cated by yellow arrows and p65 translocated into nuclear were indicated by blue arrows). Data represent the mean ± SD (n = 3). The images shown 
are the representatives of three independent experiments
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Conclusion
QDP suppressed the inflammatory responses of colonic 
macrophages in DSS-induced UC in mice and LPS-
induced RAW264.7 cells.
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